Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Exosome-enabled bone defect repair: mechanistic foundations, bioengineered delivery, and artificial intelligence-driven translation

Yang S., Ge S., Liu Z., Chen J., Chang F., Shen J.

Narrative Review on Face & Skin, published in J Nanobiotechnology (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Nanobiotechnology (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41764501
PMCID
PMC13059443
DOI
10.1186/s12951-026-04176-w
Citations
2

Abstract (original English)

Bone defects remain a substantial clinical burden. Exosomes have been extensively investigated as cell-free therapeutic candidates, exhibiting favorable biocompatibility and potential applicability in bone defect repair. Mechanisms relevant to bone regeneration are delineated, including activation of osteogenic and angiogenic programs, modulation of osteoblast-osteoclast coupling, immune regulation, and extracellular matrix remodeling. Engineering strategies that enhance targeting, stability, and potency are summarized. Delivery platforms that provide spatial and temporal control of release at defect sites are also appraised. Artificial intelligence (AI) has been examined as an accelerator of translation. Applications include high‑fidelity exosome characterization, data‑driven biomaterial and formulation design, and prediction of therapeutic response from multimodal data. Large language models further assist evidence synthesis and hypothesis generation. Persistent barriers include heterogeneity in isolation and analytics, low yield and limited scalability, lack of standardization, and insufficient validation in disease‑relevant and large‑animal models. A forward agenda emphasizes standardized manufacturing and quality control, mechanism‑informed cargo and surface engineering, responsive delivery systems and AI‑enabled design-control pipelines to realize precise and reproducible

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Bone and BonesAnimalsHumansBone DiseasesBiocompatible MaterialsDrug Delivery SystemsBone RegenerationOsteogenesisArtificial IntelligenceExosomes

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research